To further evaluate the therapeutic potential of PiHL on oxaliplatin-resistant CRC in vivo, we systemically administered an optimized LNA targeting PiHL in a 480R xenograft model (Figs. 6F and S6A). This evidence concerns the gene PCAT1 and colorectal carcinoma.